Latest News

Bruton’s tyrosine kinase (BTK) has been discovered to serve a critical role in the survival and infiltration of B-cell lymphoma. Recently, it was reported that BTK inhibitors exerted potential beneficial effects against numerous types of solid tumor, including glioblastoma multiforme and breast cancer; however, whether BTK is crucial for the progression of bladder cancer (BLCA) […]

Understanding the complex network of factors driving healthcare disparities is paramount to reducing them. Many studies have identified disparities in treatment between Black and White individuals with muscle-invasive bladder cancer (MIBC) but are limited to broad generalizations for entire racial/ethnic groups. Few studies use a conceptual framework that includes other racial/ethnic groups or examines how […]

We aim to understand, from acquired genetic alterations in tumors, why African American (AA) men are more likely to develop aggressive prostate cancer. By analyzing somatic mutations in 39 genes using deeper next-generation sequencing with an average depth of 2,522 reads for tumor DNA and genome-wide DNA copy-number alterations (CNA) in prostate cancer in a […]

San Francisco, CA (UroToday.com) — Prostate cancer tumors from African American men had higher frequencies of certain genetic alterations that may be associated with aggressive disease, compared with prostate cancer tumors from white men, according to results from a study published in Molecular Cancer Research, a journal of the American Association for Cancer Research.

In this phase II response-adaptive trial, we investigated the rational application of immune checkpoint blockade in renal cell carcinoma (RCC; ClinicalTrials.gov identifier: NCT03203473). We enrolled patients with metastatic RCC with no prior checkpoint inhibitor exposure.

Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long-term safety data. Our objective was to report long-term outcomes of two cycles of adjuvant carboplatin dosed at area under the time-concentration curve (AUC) of 7.

Morphological cocktails in renal cell carcinoma (RCC). Minimal immunohistochemistry (IHC) panel to resolve the diagnosis of renal cell cacinoma (RCC) with morphological overlaps. RCC is the most common malignancy in kidney accounting for 90% of all kidney cancers.

Clear cell renal cell carcinoma (ccRCC) is a common genitourinary cancer associated with the development of abnormal tumor angiogenesis. Although multiple anti-angiogenic therapies have been developed, responses to individual treatment are highly variable between patients.

Androgen deprivation therapy (ADT) is the standard treatment for advanced prostate cancer, but its effect on cardiovascular and metabolic function in Asian patients is still inconclusive. We prospectively assess the effects of ADT on 36 patients with advanced prostate cancer, with reference to another 24 prostate cancer patients not requiring ADT, for 2 years.

After 2008 and 2012 USPSTF recommendations against PSA screening, studies revealed a decline in screening rates and trend towards more advanced disease at presentation. After revision of this recommendation in 2017, PSA screening guidelines remain inconsistent and controversy still exists about its clinical utility.